[
  {
    "ts": null,
    "headline": "Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?",
    "summary": "ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.",
    "url": "https://finnhub.io/api/news?id=a0f85e6fcda60df631a76a2285b99db1db8b71796afe3bd0bf007f91aeb35d64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736350500,
      "headline": "Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?",
      "id": 132318353,
      "image": "https://media.zenfs.com/en/zacks.com/9f7296fade0c729cbae8baf4df367222",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.",
      "url": "https://finnhub.io/api/news?id=a0f85e6fcda60df631a76a2285b99db1db8b71796afe3bd0bf007f91aeb35d64"
    }
  },
  {
    "ts": null,
    "headline": "Insiders At Abbott Laboratories Sold US$3.0m In Stock, Alluding To Potential Weakness",
    "summary": "Over the past year, many Abbott Laboratories ( NYSE:ABT ) insiders sold a significant stake in the company which may...",
    "url": "https://finnhub.io/api/news?id=8ea28efdf290c034f29189ccce9a5e0a1b1fa331060796c0a1bb89f74ef4ed75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736341211,
      "headline": "Insiders At Abbott Laboratories Sold US$3.0m In Stock, Alluding To Potential Weakness",
      "id": 132316308,
      "image": "",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Over the past year, many Abbott Laboratories ( NYSE:ABT ) insiders sold a significant stake in the company which may...",
      "url": "https://finnhub.io/api/news?id=8ea28efdf290c034f29189ccce9a5e0a1b1fa331060796c0a1bb89f74ef4ed75"
    }
  },
  {
    "ts": null,
    "headline": "BDSX Stock Rises After Publication of Study Data for Nodify CDT Test",
    "summary": "Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.",
    "url": "https://finnhub.io/api/news?id=98bd7497c8c06483050ac08a181cd69e7f5a6f64e963132aa7124416880244ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736339400,
      "headline": "BDSX Stock Rises After Publication of Study Data for Nodify CDT Test",
      "id": 132316204,
      "image": "https://media.zenfs.com/en/zacks.com/98f062077b0e287fed47c16e0521fc3d",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.",
      "url": "https://finnhub.io/api/news?id=98bd7497c8c06483050ac08a181cd69e7f5a6f64e963132aa7124416880244ef"
    }
  },
  {
    "ts": null,
    "headline": "CURE: Analyst Estimates Point To Significant Gains In 2025",
    "summary": "The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=d511117d3542b3c924b27ade3e17e3d5a504a7d2af3c6fa8d68efe57e54c1850",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736327815,
      "headline": "CURE: Analyst Estimates Point To Significant Gains In 2025",
      "id": 132315626,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=d511117d3542b3c924b27ade3e17e3d5a504a7d2af3c6fa8d68efe57e54c1850"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories Q4 2024 Earnings Preview",
    "summary": "Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. See why I maintain my buy rating on ABT stock.",
    "url": "https://finnhub.io/api/news?id=ff4d991eea238e580d4331ee248fd3fb7989b92b6a1faa78d0f3f567a13469c8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736325021,
      "headline": "Abbott Laboratories Q4 2024 Earnings Preview",
      "id": 132315176,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160160268/image_2160160268.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. See why I maintain my buy rating on ABT stock.",
      "url": "https://finnhub.io/api/news?id=ff4d991eea238e580d4331ee248fd3fb7989b92b6a1faa78d0f3f567a13469c8"
    }
  }
]